SLC1A3

Across TCGA pan-cancer cohorts, SLC1A3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC1A3 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC1A3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC1A3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where SLC1A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.229	0.762	.010	14	view →
GBM	OS	Tertile	All	0.703	0.384	.005	9	view →
HNSC	OS	Quartile	III,IV	0.726	0.922	.022	4	view →
LSCC	DFS	Quartile	III,IV	1.000	0.286	.026	4	view →
LUAD	DFS	Quartile	All	0.723	0.384	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC1A3–PDAC (OS)

Open the PDAC breakdown →